A fiercely competitive three-horse race in spinal muscular atrophy is Evrysdi’s for the taking.
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
The first quarter of 2021 saw fewer deals than any in recent memory.
Success in a study in essential tremor is marred by a high rate of adverse events and patient dropouts.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.